| Repeat expansions confer WRN dependence in microsatellite-unstable cancers N van Wietmarschen, S Sridharan, WJ Nathan, A Tubbs, EM Chan, ... Nature 586 (7828), 292-298, 2020 | 117 | 2020 |
| CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity AC Watt, P Cejas, MJ DeCristo, O Metzger-Filho, EYN Lam, X Qiu, ... Nature Cancer 2 (1), 34-48, 2021 | 58 | 2021 |
| Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence Z Wu, J Zhou, X Zhang, Z Zhang, Y Xie, J Liu, ZV Ho, A Panda, X Qiu, ... Nature genetics 53 (6), 881-894, 2021 | 47 | 2021 |
| CoBRA: containerized bioinformatics workflow for reproducible ChIP/ATAC-seq analysis X Qiu, AS Feit, A Feiglin, Y Xie, N Kesten, L Taing, J Perkins, S Gu, Y Li, ... Genomics, Proteomics and Bioinformatics 19 (4), 652-661, 2021 | 26* | 2021 |
| FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues A Font-Tello, N Kesten, Y Xie, L Taing, D Varešlija, LS Young, AA Hamid, ... Nature Protocols, 1-16, 2020 | 21 | 2020 |
| ERG-Mediated Coregulator Complex Formation Maintains Androgen Receptor Signaling in Prostate Cancer N Shah, N Kesten, A Font-Tello, MEK Chang, R Vadhi, K Lim, MR Flory, ... Cancer Research 80 (21), 4612-4619, 2020 | 9 | 2020 |
| Distinct oncogenic signatures in malignant PEComa and leiomyosarcoma identified by integrative RNA-seq and H3K27ac ChIP-seq analysis. K Giannikou, AA Azim, E Adib, IM Schaefer, N Kesten, L Taing, Z Zhu, ... Journal of Clinical Oncology 40 (16_suppl), 11552-11552, 2022 | 1 | 2022 |
| Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, A Grinshpun, ... Clinical Cancer Research 30 (9), 1889-1905, 2024 | | 2024 |
| Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer M Alečković, Z Li, N Zhou, X Qiu, B Lulseged, P Foidart, XY Huang, ... Molecular Cancer Therapeutics 22 (11), 1304-1318, 2023 | | 2023 |
| Abstract PR014: Cytokine mediated epigenetic reprogramming of CRC primary tumors drives liver metastasis J Rennhack, A Dwivedi, N Wu, B Shim, A Font-Tello, N Kesten, A Aguirre, ... Cancer Research 83 (2_Supplement_2), PR014-PR014, 2023 | | 2023 |
| Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 … KN Lynch, JF Liu, N Kesten, KH Chow, A Shetty, R He, MF Afreen, L Yuan, ... Cancers 13 (9), 2195, 2021 | | 2021 |
| Abstract PO-010: Kidney angiomyolipomas are defined by a unique transcriptomic profile and H3K27ac chromatin state K Giannikou, CK Probst, M Zarei, X Qiu, M Duarte, N Kesten, Z Hebert, ... Cancer Research 80 (23_Supplement), PO-010-PO-010, 2020 | | 2020 |
| Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor … SJ Hill, P Lizotte, N Kesten, NS Horowitz, MG Muto, MJ Worley, ... CLINICAL CANCER RESEARCH 26 (13), 32-32, 2020 | | 2020 |
| Collective extrusion initiates dissemination in organotypic model of high-grade serous carcinoma. SJ Hill, P Lizotte, N Kesten, NS Horowitz, MG Muto, MJ Worley, ... CLINICAL CANCER RESEARCH 26 (13), 85-86, 2020 | | 2020 |
| Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and … SJ Hill, P Lizotte, N Kesten, NS Horowitz, MG Muto, MJ Worley, ... Clinical Cancer Research 26 (13_Supplement), PR06-PR06, 2020 | | 2020 |
| Lie Groups and Lie Algebras N Kesten | | 2013 |
| Selective CDK7 Inhibition Has Dual Activity in Treatment Resistant Estrogen Receptor Positive Breast Cancer C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, MJ Leventhal, ... | | |
Myles BrownEmil Frei III Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical SchoolEmail verificata su dfci.harvard.edu
